Month: September 2026

Tel-Aviv, Israel, Sept. 29, 2026 (GLOBE NEWSWIRE) — Ellomay Capital Ltd. (NYSE American; TASE: ELLO) (“Ellomay” or the “Company”), a renewable energy and power generator and developer of renewable energy and power projects in Europe, USA and Israel, announced today that its Spanish indirectly held wholly-owned subsidiary, Ellomay Solar S.L., which owns a 28 MWp solar facility in Talaván, Cáceres, Spain, received a battery storage grid access and connection permit for a project with a capacity for up to 22.2 MW /100.3 MWh (4.5-hour) (the “BESS Facility”). The BESS Facility also received a permit to charge 22.2 MW electricity from the grid. The charging permit is expected to increase the flexibility and profitability of the project.

The BESS Facility will be constructed on land already leased to Ellomay Solar. Ellomay currently expects that construction of the BESS Facility will commence in the beginning of 2027 and will be completed in the fourth quarter of 2027.

Ran Fridrich, CEO and Board member of Ellomay, said: “As previously disclosed by Ellomay, battery storage is a core growth engine for Ellomay, and we are focusing our efforts in markets where the need for flexibility is growing fastest, primarily Spain and Italy. The permit received by Ellomay Solar represents an important milestone in our strategy. The combination of solar generation and long-duration storage from Ellomay Solar’s facility and from the grid will provide a great degree of flexibility to Ellomay Solar, helping us make more effective use of renewable energy while supporting the evolving needs of the power system. We are pleased to advance the BESS Project and continue developing solutions that contribute to a more flexible and resilient energy future.”

About Ellomay Capital Ltd.

Ellomay is an Israeli based company whose shares are registered with the NYSE American and with the Tel Aviv Stock Exchange under the trading symbol “ELLO”. Since 2009, Ellomay focuses its business in the renewable energy and power sectors in Europe, USA and Israel.

To date, Ellomay has evaluated numerous opportunities and invested significant funds in the renewable, clean energy and natural resources industries in Israel, Italy, Spain, the Netherlands and USA, including:

• Approximately 335.9 MW of operating solar power plants in Spain (including a 300 MW solar plant in owned by Talasol, which is 51% owned by the Company) and 51% of approximately 48 MW of operating solar power plants in Italy;
   
• Groen Gas Goor B.V., Groen Gas Oude-Tonge B.V. and Groen Gas Gelderland B.V., project companies operating anaerobic digestion plants in the Netherlands, with a green gas production capacity of approximately 3 million, 3.8 million and 9.5 million Nm3 per year, respectively;
   
• 83.333% of Ellomay Pumped Storage (2014) Ltd., which is involved in a project to construct a 156 MW pumped storage hydro power plant in the Manara Cliff, Israel;
   
• 51% of solar projects in Italy with an aggregate capacity of 150 MW that are under construction;
   
• Solar projects in Italy with an aggregate capacity of 227 MW that have reached “ready to build” status; and
   
• Solar projects in the Dallas Metropolitan area, Texas, USA with an aggregate capacity of approximately 49 MW that are connected to the grid and 14 MW that is awaiting connection to the grid.

For more information about Ellomay, visit http://www.ellomay.com.

Information Relating to Forward-Looking Statements

This press release contains forward-looking statements that involve substantial risks and uncertainties, including statements that are based on the current expectations and assumptions of the Company’s management. All statements, other than statements of historical facts, included in this press release regarding the Company’s plans and objectives, expectations and assumptions of management are forward-looking statements. The use of certain words, including the words “estimate,” “project,” “intend,” “expect,” “believe” and similar expressions are intended to identify forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The Company may not actually achieve the plans, intentions or expectations disclosed in the forward-looking statements and you should not place undue reliance on the Company’s forward-looking statements. Various important factors could cause actual results or events to differ materially from those that may be expressed or implied by the Company’s forward-looking statements, including delays and difficulties in commencing and finalizing the construction of the BESS Facility, changes in electricity prices and demand, regulatory changes increases in interest rates and inflation, changes in the supply and prices of resources required for the operation of the Company’s facilities (such as waste and natural gas) and in the price of oil, the impact of the war and hostilities in Israel and Gaza and between Israel and Iran, the impact of the continued military conflict between Russia and Ukraine, technical and other disruptions in the operations or construction of the power plants owned by the Company, inability to obtain the financing required for the development and construction of projects, increases in interest rates and inflation, changes in exchange rates, delays in development, construction, or commencement of operation of the projects under development, failure to obtain permits – whether within the set time frame or at all, climate change, and general market, political and economic conditions in the countries in which the Company operates, including Israel, Spain, Italy and the United States. These and other risks and uncertainties associated with the Company’s business are described in greater detail in the filings the Company makes from time to time with the Securities and Exchange Commission, including its Annual Report on Form 20-F. The forward-looking statements are made as of this date and the Company does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:

Kalia Rubenbach (Weintraub)
CFO
Tel: +972 (3) 797-1111
Email: hilai@ellomay.com

New awards expand contracted business visibility across YYForce’s Singapore integrated facility management operations, with all contracts commencing in October 2026 and principal service periods extending approximately three years

SINGAPORE, Sept. 29, 2026 (GLOBE NEWSWIRE) — YYForce Inc. (Nasdaq: YFOR) (“YYForce” or the “Company”), an AI-enabled workforce management and integrated facility management (“IFM”) provider, today announced that its Singapore subsidiary, Hong Ye Group Pte. Ltd. (“Hong Ye Group”), has been awarded multiple new commercial cleaning and related facility services contracts in Singapore with an aggregate contract value of approximately S$15.96 million (approximately US$12.5 million).

The newly awarded contracts cover multiple properties in Singapore, are scheduled to commence across October 2026, and have varying service periods, with the principal contracts extending for approximately three years. Based on current contractual schedules, aggregate contract values are expected to be approximately S$5.57 million in Year 1, S$5.55 million in Year 2 and S$4.84 million in Year 3.

Key Contract Facts

Metric	Details
Aggregate Contract Value	Approximately S$15.96 million
Business Unit	Hong Ye Group Pte. Ltd., YYForce’s Singapore subsidiary
Services	Commercial cleaning and related facility services
Market	Singapore
Contract Commencement	October 2026
Principal Contract Duration	Approximately three years
Year 1 Contract Value	Approximately S$5.57 million
Year 2 Contract Value	Approximately S$5.55 million
Year 3 Contract Value	Approximately S$4.84 million

Expanding Multi-Year Contracted Business Visibility

The new awards expand Hong Ye Group’s portfolio of contracted commercial cleaning and facility services work in Singapore and provide YYForce with additional multi-year contracted business visibility, supported by a unified contract commencement in October 2026.

The awards follow YYForce’s recently reported first-half 2026 results, in which IFM revenue increased 11.1% year over year to approximately US$16.06 million. The Company reported that IFM growth in the period was supported by new contract wins, renewals of existing projects and full-period contributions from subsidiaries acquired in 2025.

Contract Value and Revenue Recognition. Aggregate contract value is distinct from revenue recognized for accounting purposes. With all contracts commencing in October 2026, actual revenue recognition will depend on ongoing service delivery, contractual terms, customer requirements and applicable accounting standards. There can be no assurance that the full aggregate contract value will be recognized as revenue according to the current anticipated schedule.

Executive Commentary

“These new multi-year contract awards expand our commercial services business in Singapore and strengthen the contracted business visibility of Hong Ye Group as we head into our October commencement,” said Mike Fu, Chief Executive Officer of YYForce.

“As we execute our integrated facility management strategy, our focus is on combining disciplined frontline service delivery with workforce technology, intelligent scheduling, AI and automation. These contracts expand the operating base through which we can continue improving productivity, service consistency and scalability over time.”

Supporting YYForce’s Integrated Facility Management Strategy

Hong Ye Group is an important component of YYForce’s IFM operations in Singapore. YYForce’s strategy is to combine established frontline facility services with technology-enabled workforce management and, over time, increasing levels of AI, automation and robotics.

Human Workforce + Workforce Technology + IFM + AI + Automation + Robotics

The Company believes this model can support improved workforce deployment, service consistency, operating efficiency and scalability. The newly awarded contracts provide an expanded operating base through which YYForce can continue developing and deploying technology-enabled solutions within its facility services operations.

About YYForce Inc.

YYForce Inc. (Nasdaq: YFOR) is an AI-enabled workforce management and integrated facility management provider headquartered in Singapore and operating across Asia and beyond. Through its workforce technology and IFM businesses, YYForce provides workforce deployment, management and facility services solutions across multiple service industries.

The Company’s workforce platform, YY Circle, supports workforce deployment and management across sectors including hospitality, food and beverage, retail and other service industries. Within its IFM operations, YYForce combines frontline facility services with technology solutions designed to improve workforce productivity and operational efficiency.

YYForce’s long-term strategy is centered on building an integrated future workforce ecosystem in which human workers, intelligent software, automation and robotics increasingly work together to deliver services more efficiently.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements may be identified by words such as “may,” “will,” “should,” “expects,” “anticipates,” “estimates,” “believes,” “plans,” “intends,” “projects,” “predicts,” “potential,” “continue,” “target,” or similar expressions.

These forward-looking statements include, among other things, statements regarding anticipated contract performance and revenue recognition, the Company’s integrated facility management strategy, the integration of workforce technology, artificial intelligence, automation and robotics into its operations, operational efficiency, scalability and future growth strategy.

Forward-looking statements are based on current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied. These risks and uncertainties include, among others, customer requirements, contract commencement and performance, labor availability and costs, competitive conditions, economic and market conditions, technology implementation, regulatory developments and other risks described in YYForce’s filings with the U.S. Securities and Exchange Commission.

Readers are encouraged to review the Company’s filings with the SEC, including the “Risk Factors” section of its most recent annual report on Form 20-F and subsequent filings. YYForce undertakes no obligation to publicly update or revise any forward-looking statements except as required by applicable law.

Investor Relations Contacts

Jason Zhi Yong Phua
Chief Financial Officer
YYForce Inc.
enquiries@yyforce.ai

Piacente Financial Communications
yfor@thepiacentegroup.com

RADNOR, Pa., Sept. 29, 2026 (GLOBE NEWSWIRE) — Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone, announced today that, on September 28, 2026, the Compensation Committee of Mineralys’ Board of Directors granted inducement stock option awards covering an aggregate of 46,430 shares and inducement restricted stock unit awards covering an aggregate of 34,823 shares of Mineralys common stock to two new non-executive employees.

The awards were granted under Mineralys’ 2025 Employment Inducement Incentive Award Plan, which provides for the granting of equity awards to new employees of Mineralys. The option awards will vest over a four-year period, with 25% of the total shares underlying the awards vesting on the first anniversary of the awards’ vesting commencement date, September 28, 2026, and 1/48th of the total shares underlying the awards vesting following each one-month period thereafter, subject to continued service. The restricted stock unit awards will vest over a four-year period, with 25% of the shares vesting on each of the first four anniversaries of the awards’ vesting commencement date, September 28, 2026, subject to continued service. The awards were granted as an inducement material to the new non-executive employees entering into employment with Mineralys, in accordance with Nasdaq Listing Rule 5635(c)(4).

About Mineralys

Mineralys Therapeutics is a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is an investigational, proprietary, orally administered, highly selective aldosterone synthase inhibitor. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit https://mineralystx.com. Follow Mineralys on LinkedIn, X and Bluesky.

Contact:

Investor Relations

investorrelations@mineralystx.com

BALA CYNWYD, Pa., Sept. 29, 2026 (GLOBE NEWSWIRE) — Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the appointment of John Harlow as President and Chief Operating Officer, effective September 29, 2026, reporting to Carole Ben-Maimon, M.D., Larimar’s Chief Executive Officer. Mr. Harlow joins Larimar with more than 25 years of commercial, operational and business development experience across the biopharmaceutical industry.

“As nomlabofusp advances toward potential approval, we are excited to welcome John to our executive team,” said Carole Ben-Maimon, M.D., Chief Executive Officer of Larimar. “His commercial and operational leadership, coupled with his proven ability to translate strategy into execution, will be instrumental as we scale the organization and prepare to bring nomlabofusp to patients worldwide.”

Mr. Harlow added, “Larimar has a unique opportunity to deliver the first potential disease-modifying therapy for adults and pediatric patients living with Friedreich’s ataxia. I look forward to working with Carole and this talented team to deliver a successful launch and position the company for long-term growth.”

Most recently, he served as Chief Commercial Officer of Esperion Therapeutics, where he led commercial operations, business development and global alliance management. Previously, he served as Chief Commercial Officer of Melinta Therapeutics, where he built a robust commercial infrastructure with a high-performing team while achieving significant revenue growth and sustained profitability ahead of its 2025 acquisition by CorMedix. Earlier in his career, Mr. Harlow held executive leadership roles at Baudax Bio, Recro Pharma and Endo Pharmaceuticals, as well as commercial and marketing leadership roles at Shionogi, Alpharma/King Pharmaceuticals, Novartis and Janssen. His earlier experience also includes serving as an equity research analyst at Merrill Lynch. Mr. Harlow holds an MBA in Pharmaceutical Management from Seton Hall University and a BS in Biology from Lehigh University.

Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

In connection with Mr. Harlow’s appointment, the Compensation Committee of the Board of Directors of the Company approved an inducement award, in accordance with Nasdaq Listing Rule 5635(c)(4), to Mr. Harlow, to be granted on September 29, 2026 consisting of a (i) non-qualified stock option (“Option Award”) to purchase 800,000 shares of the Company’s common stock at an exercise price equal to the closing price per share of the Company’s common stock as reported on the Nasdaq Global Market on the date of grant and (ii) restricted stock unit award in respect of 50,000 shares of the Company’s common stock (“RSU Award” and together with the Option Award, the “Equity Awards”). The Equity Awards were granted as an inducement material to his acceptance of employment as President and Chief Operating Officer of the Company. The Option Award will vest over a four-year period, with 25% of the Option Award vesting on the first anniversary of the date of grant, and the remaining 75% of the Option Award vesting in substantially equal monthly installments over thirty-six (36) months. The RSU Award will vest in four (4) substantially equal annual installments, beginning on the first anniversary of the date of grant. The Equity Awards are subject to Mr. Harlow’s continued service with the Company through the applicable vesting dates and were granted outside the terms of the Company’s 2020 Equity Incentive Plan.

About Larimar Therapeutics
Larimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Larimar’s lead compound, nomlabofusp, is being developed as a potential treatment for Friedreich’s ataxia. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. For more information, please visit: https://larimartx.com.

Forward-Looking Statements
This press release contains forward-looking statements that are based on Larimar’s management’s beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including but not limited to statements regarding Larimar’s ability to develop and commercialize nomlabofusp and any other planned product candidates, Larimar’s planned research and development efforts, including the timing of its nomlabofusp clinical trials, dosing of the first patient in a global confirmatory Phase 3 study, interactions and filings with the FDA, the safety and therapeutic potential of nomlabofusp, expectations regarding the timing of completion of the BLA submission, the expectations of the timing of, and potential for, accelerated approval or accelerated access, time to launch and market and overall development plans and other matters regarding Larimar’s business strategies, ability to raise capital, use of capital, results of operations and financial position, and plans and objectives for future operations.

In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors include, among others, the success, cost and timing of Larimar’s product development activities, nonclinical studies and clinical trials, including nomlabofusp clinical milestones and continued interactions with the FDA; that preliminary clinical trial results may differ from final clinical trial results, that earlier non-clinical and clinical data and testing of nomlabofusp may not be predictive of the results or success of later non-clinical or clinical trials, and assessments; delays in patient recruitment, including as a result of changes in clinical protocols and adverse events; that the FDA may not ultimately agree with Larimar’s nomlabofusp development strategy; Larimar’s ability to submit BLA modules on the intended timeline; Larimar’s ability to realize the benefits of Breakthrough Therapy Designation; the potential impact of public health crises on Larimar’s future clinical trials, manufacturing, regulatory, nonclinical study timelines and operations, and general economic conditions; Larimar’s ability and the ability of third-party manufacturers Larimar engages, to optimize and scale nomlabofusp’s manufacturing process; Larimar’s ability to obtain regulatory approvals for nomlabofusp and future product candidates; Larimar’s ability to develop sales and marketing capabilities, whether alone or with potential future collaborators, and to successfully commercialize any approved product candidates; Larimar’s ability to raise the necessary capital to conduct its product development activities; and other risks described in the filings made by Larimar with the Securities and Exchange Commission (SEC), including but not limited to Larimar’s periodic reports, including the annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K, filed with or furnished to the SEC and available at www.sec.gov. These forward-looking statements are based on a combination of facts and factors currently known by Larimar and its projections of the future, about which it cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent Larimar’s management’s views only as of the date hereof. Larimar undertakes no obligation to update any forward-looking statements for any reason, except as required by law.

Investor Contact: Joyce Allaire LifeSci Advisors jallaire@lifesciadvisors.com (212) 915-2569

Company Contact: Michael Celano Chief Financial Officer mcelano@larimartx.com (484) 414-2715

• Companies will collaborate to develop advanced memory structures, chip stacking technologies and materials engineering innovations to increase AI memory performance
• KIOXIA joins Applied Materials’ growing EPIC Center ecosystem, which includes chipmakers, chip designers, equipment partners and universities

SANTA CLARA, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) — Applied Materials, Inc., the leader in materials engineering solutions for the semiconductor industry, today announced that KIOXIA Corporation, a leading global supplier of flash memory and solid state drives (SSDs), will join Applied’s EPIC Center in Silicon Valley as an innovation partner to advance next-generation memory technologies. The companies will work together at the EPIC Center on advanced memory-cell and structure creation, multi-chip stacking architectures, and new materials engineering approaches designed to increase memory density and performance for the AI era.

“AI infrastructure requires memory solutions that can deliver dramatically higher density, greater bandwidth and improved energy efficiency,” said Gary Dickerson, President and CEO of Applied Materials. “By bringing KIOXIA’s deep expertise in memory technology together with Applied’s materials engineering innovations at the EPIC Center, we’re creating a powerful partnership to define what’s possible in next-generation memory.”

“At KIOXIA, we have always believed that the possibility of memory is defined by the ability to stretch the boundaries of materials and process innovation,” said Hiroo Ota, President and CEO of KIOXIA Corporation. “Our collaboration with Applied Materials reflects our shared commitment to driving memory innovation, and we are excited to partner at the EPIC Center to achieve advanced breakthroughs.”

Through the EPIC Center partnership, Applied Materials and KIOXIA will collaborate on R&D initiatives focused on the most critical challenges in next-generation memory innovation. Areas of focus include:

• Advanced memory cell and structure creation to develop more capable, higher-density memory architectures for AI applications
• Multi-chip stacking for next-generation memory to enable chip integration that increases memory density and performance within constrained form factors
• Advanced packaging for stacked memory to improve integration and interconnect performance in complex multi-die memory solutions
• Materials engineering innovations that enable next-generation memory structures while supporting manufacturability at scale

“Memory is at the center of the AI innovation roadmap, and the challenges of increasing memory density while managing cost and complexity require breakthroughs across materials, equipment and process technology,” said Dr. Prabu Raja, President of the Semiconductor Products Group at Applied Materials. “We look forward to partnering with KIOXIA at the EPIC Center, where our teams will drive advances in AI memory through deep co-innovation.”

“Partnering with Applied Materials at the EPIC Center gives us a unique environment to tackle the hardest challenges in next-generation memory,” said Minori Kajimoto, General Manager of Advanced Memory Development at KIOXIA. “By having top innovators from KIOXIA and Applied Materials working side by side, we aim to accelerate the commercialization of breakthroughs in memory and packaging technologies that achieve new levels of integration and performance for AI computing.”

Applied’s new, $5 billion* EPIC (Equipment and Process Innovation and Commercialization) Center in Silicon Valley represents the largest-ever U.S. investment in advanced semiconductor equipment R&D. The center, which will be operationally ready this year, is designed from the ground up to dramatically reduce the time it takes to commercialize breakthrough technologies from early-stage research to full-scale manufacturing. For chipmakers, the EPIC Center will provide earlier access to Applied’s R&D portfolio, faster cycles of learning and accelerated transfer of next-generation technologies into high-volume manufacturing, within a secure collaborative environment. In addition, the co-innovation programs at the EPIC Center will provide Applied with greater multi-node visibility to guide R&D investments while increasing R&D productivity and value sharing.

*Capital spending is expected to scale over time to approximately $5 billion as customer projects commence.

Forward-Looking Statements
This press release contains forward-looking statements, including those regarding Applied’s investment and growth strategies, the development of new materials and technologies, industry outlook and technology requirements, the plans and expectations for the EPIC Center, and other statements that are not historical facts. These statements and their underlying assumptions are subject to risks and uncertainties and are not guarantees of future performance. Factors that could cause actual results to differ materially from those expressed or implied by such statements include, without limitation: the demand for semiconductors and customers’ technology requirements; the ability to develop new and innovative technologies; the ability to obtain and protect intellectual property rights in key technologies; the ability to achieve the objectives of the EPIC Center; and other risks and uncertainties described in Applied’s filings with the Securities and Exchange Commission, including Applied’s most recent Forms 10-K, 10-Q and 8-K. All forward-looking statements are based on management’s current estimates, projections and assumptions, and Applied assumes no obligation to update them.

About Applied Materials
Applied Materials, Inc. (Nasdaq: AMAT) is the leader in materials engineering solutions that are at the foundation of virtually every new semiconductor and advanced display in the world. The technology we create is essential to advancing AI and accelerating the commercialization of next-generation chips. At Applied, we push the boundaries of science and engineering to deliver material innovation that changes the world. Learn more at www.appliedmaterials.com.

Contacts:

Applied Materials
Ricky Gradwohl (editorial/media) 408.235.4676
Mike Sullivan (financial community) 408.986.7977

Definitive share purchase agreement implements the previously announced binding commitment for Brooks Campus #1; cash consideration of US$2.3 million on a cash-free, debt-free basis; closing targeted on or before October 29, 2026

WEST PALM BEACH, Fla., Sept. 29, 2026 (GLOBE NEWSWIRE) — FingerMotion, Inc. (Nasdaq: FNGR) (“FingerMotion” or the “Company”) today announced that it has entered into a definitive Share Purchase Agreement dated as of September 23, 2026 (the “Agreement”) with individual shareholders of Newbit (the “Vendors”) and Newbit Technology Inc. (“Newbit” or the “Target”), a British Columbia corporation extra-provincially registered in Alberta.

Under the Agreement, FingerMotion has agreed to purchase 100% of the issued and outstanding shares of Newbit for a purchase price of US$2,300,000 in cash, exclusive of GST, on a cash-free, debt-free basis, subject to customary leakage and debt adjustments. Newbit holds the surface tenure, development and building permits, pipeline and metering infrastructure, environmental and Alberta Utilities Commission Rule 007 registration, and related rights associated with the Company’s previously disclosed 9.9 MW behind-the-meter site in the County of Newell, Alberta (Brooks Campus #1), identified at approximately 50.469862° N, 111.602257° W.

The Agreement restates and implements the binding memorandum of understanding dated September 8, 2026 and the binding commitment announced by the Company on September 10, 2026. A deposit of US$230,000 was previously paid and is held in trust. A further deposit of US$230,000 is payable on execution of the Agreement. The remaining approximately US$1,840,000 is payable in cash at closing. There is no indemnity holdback or escrow. Closing is targeted for the third business day after satisfaction or waiver of conditions, and in any event on or before the outside date of October 29, 2026.

Included rights and assets at closing (subject to permitted encumbrances)

• Surface lease of the Site with the Board of Trustees of the Eastern Irrigation District, including renewal and extension rights
• County of Newell Development Permit 2022055 and associated building and electrical permits
• Master Road Use Agreement with Canadian Natural Resources Limited
• Pipeline right of way and gas receipt and delivery infrastructure serving the Site
• Environmental Protection and Enhancement Act (Alberta) approval and AUC Rule 007 registration in respect of the isolated generating unit at the Site
• Fixed civil works, foundations, hardstand, drainage, fencing and related site studies

Generating equipment and other movable plant are excluded and are to be removed before closing. The Company is acquiring the Target, and therefore the fixed improvements, on an as-is, where-is basis as to physical condition only. Title, permits, environmental matters and absence of encumbrances remain the subject of the Agreement’s representations, conditions and indemnities.

Gas supply

The prior gas supply agreement relating to the Site has been terminated following cessation of offtake. Newbit and Pivotal Energy Partners have entered into a letter of intent for a new gas supply agreement. Following execution of the Agreement and payment of the further deposit, Newbit is obligated to arrange execution of a new gas supply agreement between Pivotal and FingerMotion (or, at FingerMotion’s election, Newbit) on terms consistent with that letter of intent and otherwise acceptable to FingerMotion, acting reasonably. FingerMotion will be responsible for any deposit or security required under the new gas supply agreement. Execution of the new gas supply agreement, together with Pivotal’s written consent to the change of control, is a condition to FingerMotion’s obligation to close.

Other principal conditions and terms

FingerMotion’s obligation to close is also conditioned on, among other things: written consent of the Eastern Irrigation District to the change of control and any required lease assignment; confirmation that the shares and included assets are free and clear of encumbrances other than permitted encumbrances and that no material adverse effect has occurred; delivery of customary closing instruments; accuracy of representations; and completion of remaining due diligence to FingerMotion’s reasonable satisfaction. Approval of the AUC for any change of generating units is not a closing condition and is FingerMotion’s post-closing responsibility.

The Vendors have agreed to joint and several indemnities, including for pre-closing taxes, financial debt, leakage, title and specified environmental matters arising from the Target’s operations. General representation claims are subject to a US$125,000 deductible and a cap of US$460,000 (20% of the purchase price). Fundamental representations, title, tax, fraud and willful misconduct are uncapped. FingerMotion will not retain a purchase-price holdback.

About FingerMotion, Inc.

FingerMotion, Inc. (Nasdaq: FNGR) is a technology company that, in addition to its historical mobile data and telecommunications platforms, is developing a North American behind-the-meter power and compute program in Alberta. Additional information is available at www.fingermotion.com.

Forward-looking statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding expected closing, timing, consents, a new gas supply agreement, development of the Site, and the Company’s 99 MW Alberta program. Forward-looking statements are subject to risks and uncertainties, including failure to satisfy closing conditions by the outside date of October 29, 2026, forfeiture or return of deposits, counterparty and regulatory risk, physical condition of on-site improvements, commodity and construction risk, financing risk, and the risk that indications of interest do not become binding offtake. The Agreement is an acquisition of shares of a holding vehicle for land, permits and infrastructure; it does not by itself create operating generation or contracted compute revenue. The Company acquires the fixed improvements as-is as to physical condition. Actual results may differ materially. The Company undertakes no obligation to update these statements except as required by law.

Investor contact
FingerMotion, Inc.
Investor Relations
Email: ir@fingermotion.com
Website: www.fingermotion.com

Mac McFarland to retire as CEO at year-end and serve as senior advisor through March 2027

Upsizes share repurchase program to a total of $3.0 billion through 2028

HOUSTON, Sept. 29, 2026 (GLOBE NEWSWIRE) — Talen Energy Corporation (“Talen,” the “Company,” “we” or “our”) (NASDAQ: TLN), a leading independent power producer, today announced a planned CEO succession, $1.5 billion accelerated share repurchase transactions (“ASRs”) and an upsized $3.0 billion share repurchase program (“SRP”).

The Board of Directors (the “Board”) has named Terry Nutt as Talen’s next Chief Executive Officer (“CEO”), effective January 1, 2027. Mr. Nutt, currently Talen’s President, will also join the Board upon his appointment as CEO. Mac McFarland will remain CEO and a member of the Board through December 31, 2026, and will then serve as a senior advisor until his retirement in March 2027. The transition period is intended to support an orderly handoff and continuity in the Company’s strategy, operations and capital allocation priorities.

“Terry is the right leader to be Talen’s next CEO,” said Stephen Schaefer, Chairman of the Board. “He combines broad industry experience with deep knowledge of Talen’s assets, people and strategy. As President and previously as Chief Financial Officer, he has helped lead the Company’s operations, commercial activities and capital allocation. The Board has worked closely with Terry over the past three-plus years and has complete confidence in his ability to build on Talen’s strong performance and continue its focus on shareholder value.”

“I am honored to succeed Mac and grateful for his leadership and mentorship,” said Mr. Nutt. “As I prepare to lead Talen, my priorities are clear: maintain safe and reliable operations, execute Talen’s flywheel strategy and allocate capital with discipline. Today’s ASRs reflect that approach by reducing our share count at what we believe is an attractive free cash flow yield, while preserving liquidity and strategic flexibility.”

“It has been a privilege to work alongside Talen’s employees to build a company grounded in operational excellence and a relentless focus on creating value for our shareholders,” said Mr. McFarland. “What we have accomplished has been a true team effort — across our leadership and throughout Talen. Terry knows our company, our people, our markets and our opportunities, and he is the right person to lead this team forward. I look forward to supporting him and the entire team through the transition, and I am confident Talen is well positioned for continued success under his leadership.”

Mr. Schaefer added, “Mac’s vision, discipline and focus on results have had a lasting impact on Talen. Under his leadership, the Company strengthened its operations, expanded its growth opportunities and delivered substantial value for shareholders. On behalf of the Board, I thank Mac for his leadership and contributions.”

Jonathan Krautmann, Partner at Rubric Capital Management, added, “During Mac’s tenure, Talen built an exceptional record of disciplined execution and value creation, and we thank him for the foundation he has laid. As Talen’s largest actively managed shareholder, we are deeply invested in this management team and Board, and we have seen firsthand how integral Terry has been to that success — across the balance sheet, capital allocation and commercial strategy. We congratulate Terry on his appointment as CEO. We have full confidence in his leadership and strongly support him and the entire Talen team as they build on the Company’s momentum and continue to create value for all shareholders.”

“As a significant shareholder of Talen, Energy Capital Partners is proud of what the Company has accomplished and excited about its future,” said Andrew Gilbert, Partner at Energy Capital Partners. “We thank Mac for his leadership and the significant value he and the Talen team have created. Talen is well positioned, with an exceptional team and meaningful opportunities ahead. We congratulate Terry on his appointment and are confident he is the right leader to build on this foundation and guide Talen through its next phase of growth and value creation.”

About Terry Nutt

Mr. Nutt has more than 25 years of experience in the deregulated energy industry. He has served as Talen’s President since December 2025, overseeing the Company’s operations, commercial activities, administrative functions and external affairs. He previously served as Talen’s Chief Financial Officer from July 2023 through December 2025.

Before joining Talen, Mr. Nutt was Chief Financial Officer and Managing Director of EDF Trading North America from 2018 to 2023. Earlier, he held senior finance and risk management roles at Vistra Corporation and its predecessor entities. He earned an M.S. in Accounting and a B.B.A., summa cum laude, from Texas A&M University.

Mr. Nutt has entered into a new employment agreement reflecting his responsibilities as CEO. The agreement has an initial term through February 28, 2028, followed by automatic one-year renewals unless either party provides 90 days’ written notice of nonrenewal.

SRP and ASRs

The Board also increased the remaining capacity under Talen’s SRP to $3.0 billion through December 31, 2028. The authorization includes the $1.5 billion ASR agreements announced today, leaving $1.5 billion available for further repurchases through 2028, in addition to the ASRs and repurchases completed before today. Talen has repurchased 600,000 shares quarter-to-date in the third quarter of 2026.

The uncollared ASRs are expected to be completed by the end of the first quarter of 2027 and, at the current stock price, would repurchase more than 10% of Talen’s shares outstanding. The final number of shares repurchased pursuant to the ASRs will be based on the arithmetic average of the daily volume-weighted average prices of Talen’s common stock during the ASRs’ terms, less an agreed discount and subject to customary adjustments. The ASRs are expected to be accretive to free cash flow per share.

Talen expects to fund the ASRs principally through the monetization of approximately $1.5 billion of cleared capacity revenues associated with the PJM 2027/2028 and 2028/2029 delivery years. The capacity monetization was executed with Citi at a rate of SOFR + 200 basis points. The transaction brings forward a portion of contracted future cash flows while maintaining Talen’s liquidity position, consistent with its targeted net leverage ratio of 3.5x. Talen expects to meet the targeted net leverage level during the second half of 2027, and that level is expected to decline further as the associated capacity revenues are generated and the remaining obligation is reduced.

Talen forecasts approximately $4 billion of adjusted free cash flow from 2H 2026 through year-end 2028, supported by locked-in and highly visible cash flows. After giving effect to the monetized capacity revenues, the Company expects approximately $2.8 billion of adjusted free cash flow during that period, preserving capacity for additional repurchases, strategic investments and other value-enhancing opportunities.

“Talen’s strong balance sheet, durable cash flow outlook and disciplined capital allocation framework provide us with the flexibility to return substantial capital to shareholders while maintaining our financial strength,” said Cole Muller, Talen’s Chief Financial Officer. “This accelerated repurchase reflects our confidence in Talen and the strength of our future cash flows and allows us to acquire a meaningful number of shares at what we believe are highly attractive free cash flow yields. After executing this transaction, Talen will have bought back approximately one-third of the shares outstanding at emergence three years ago. We continue to have a direct line of sight to achieving our targeted net leverage ratio of 3.5x by the second half of 2027.”

Under the ASR agreements with Goldman Sachs & Co. LLC and Banco Santander, S.A., Talen will pay an aggregate of $1.5 billion and will initially receive approximately 4.0 million shares, or about 80% of the expected number of shares to be repurchased assuming the share price at market close on September 28, 2026. At final settlement, depending on the average of the daily volume-weighted average price of Talen’s common stock over the terms of the ASRs (less an agreed discount and subject to customary adjustments), Talen may receive additional shares or, in certain circumstances, be required to make a settlement payment in cash or shares at the Company’s election and subject to the terms of the agreements.

The timing and amount of any repurchases under the remaining $1.5 billion of SRP capacity will depend on market conditions, the Company’s capital needs and other factors. The Board’s approval of the $3.0 billion SRP capacity does not obligate Talen to repurchase any particular amount of common stock beyond the ASRs, and the SRP may be suspended, modified or discontinued at any time.

About Talen

Talen Energy (NASDAQ: TLN) is a leading independent power producer and energy infrastructure company dedicated to powering the future. We own and operate approximately 15.5 gigawatts of power infrastructure in the United States, including 2.2 gigawatts of nuclear power and a significant dispatchable fossil fleet. We produce and sell electricity, capacity and ancillary services into wholesale U.S. power markets, with generation in the Mid-Atlantic, Ohio, Indiana and Montana. Our team is committed to generating power safely and reliably while delivering the most value per megawatt produced. Talen is also powering the digital infrastructure revolution. We are well positioned to serve this growing industry, as artificial intelligence data centers increasingly demand more reliable power. Talen is headquartered in Houston, Texas. For more information, visit https://www.talenenergy.com/.

Investor Relations
Bill Appicelli
Senior Vice President, Investor Relations
InvestorRelations@talenenergy.com

Media
Taryne Williams
Director, Corporate Communications
Taryne.Williams@talenenergy.com

Forward-Looking Statements

This communication contains forward-looking statements within the meaning of the federal securities laws, which statements are subject to substantial risks and uncertainties. These forward-looking statements are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact included in this communication, or incorporated by reference into this communication, are forward-looking statements. Throughout this communication, we have attempted to identify forward-looking statements by using words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecasts,” “goal,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” “will,” or other forms of these words or similar words or expressions or the negative thereof, although not all forward-looking statements contain these terms. Forward-looking statements address future events and conditions concerning, among other things, the leadership transition, the timing, size, completion, and impacts of the capacity monetization, ASR, and remaining SRP, capital expenditures, earnings, litigation, regulatory matters, hedging, liquidity and capital resources, accounting matters, expectations, beliefs, plans, objectives, goals, strategies, future events or performance, shareholder returns and underlying assumptions.

Forward-looking statements are subject to substantial risks and uncertainties that could cause our future business, financial condition, results of operations or performance to differ materially from our historical results or those expressed or implied in any forward-looking statement contained in this communication. All of our forward-looking statements include assumptions underlying or relating to such statements that may cause actual results to differ materially from expectations and are subject to numerous factors that present considerable risks and uncertainties.

Non-GAAP Financial Measures

This press release refers to adjusted free cash flow, which is not a financial measure prepared under GAAP. Non-GAAP financial measures do not have definitions under GAAP and may be defined and calculated differently by, and not be comparable to, similarly titled measures used by other companies. Non-GAAP measures have limitations as analytical tools and should not be considered in isolation or as a substitute for analyzing our results as reported under GAAP. Please see our August 5, 2026 earnings presentation for a definition of adjusted free cash flow, additional information regarding its uses and limitations, and a reconciliation to the most directly comparable GAAP measure.

New preclinical data further characterize EQ504’s effects on epithelial barrier repair and immune regulation

LA JOLLA, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) — Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that new preclinical data from its EQ504 program will be presented in two posters at the 7th International AHR Conference, taking place September 29 to October 2, 2026, in Porto, Portugal.

“These studies further characterize the multi-modal activity of EQ504, including its effects on epithelial barrier repair and key immune pathways involved in inflammation,” said Dr. Stephen Connelly, Chief Scientific Officer of Equillium. “Together, the findings add to the growing body of preclinical data supporting the potential of selective AhR modulation as an approach to treating ulcerative colitis.”

Details of the poster presentations:

Title: Selective AhR Activation Suppresses Epithelial Chemokine Production and Promotes Barrier Repair Responses in Translational Models of Ulcerative Colitis
Abstract Number: P.43
Poster Number: 89
Lead Author: Valeria Marrocco, Mary Casis, Michelle Vu, A.J. Giovannone, Jeanette Ampudia, Phoi Tiet, Stephen Connelly
Presentation Type: Poster Session
Presentation Summary: EQ504 engages AhR to protect intestinal barrier integrity through complementary epithelial and immune-modulatory mechanisms, including regulation of tight-junction proteins, inflammatory chemokines, and homeostatic cytokines. Across in vitro, translational, and in vivo models, these findings support the therapeutic potential of EQ504 for the treatment of ulcerative colitis.

Title: AhR Modulation by EQ504 Restores Immune Balance by Suppressing Pathogenic Th17/M1 Responses While Enhancing Regulatory Pathways
Abstract Number: P.39
Poster Number: 84
Lead Author: Jeanette Ampudia, Rosa Closser, Phoi Tiet, Valeria Marrocco, Stephen Connelly
Presentation Type: Poster Session
Presentation Summary: EQ504 promotes immune tolerance by modulating AhR signaling to coordinate both adaptive and innate immune responses, increasing tolerance while suppressing pro-inflammatory pathways. This unique immunoregulatory profile supports tissue repair and intestinal homeostasis, highlighting EQ504’s potential as a therapeutic approach for inflammatory bowel disease and other immune-mediated disorders. 

Following each presentation, the posters will be available on the Presentations page located under the Technology section of equilliumbio.com.

About EQ504
EQ504 is an investigational potent and selective aryl hydrocarbon receptor (AhR) modulator with a multi-modal, non-immunosuppressive mechanism of action designed to be complementary to other inflammation and immunology agents. AhR is critical to barrier organ tissue physiology and immunology, maintaining barrier function and promoting tissue repair and regeneration, while regulating resident immune cells with anti-inflammatory responses. EQ504’s preclinical properties provide the potential for targeted, local delivery via enteric coating for the treatment of ulcerative colitis and other gastrointestinal diseases or inhaled formulations for the treatment of inflammatory lung diseases.

About Equillium
Equillium is a biotechnology innovator with a mission to develop highly impactful therapies to treat severe autoimmune and inflammatory disorders. 

For more information, visit www.equilliumbio.com.

Forward Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate”, “believe”, “could”, “continue”, “expect”, “estimate”, “may”, “plan”, “outlook”, “future”, “potential” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These statements include, but are not limited to, statements regarding Equillium’s plans and strategies with respect to developing EQ504, including the initiation of clinical studies and the reporting of data therefrom; the expected timeline for initiating and reporting data from a Phase 1 study of EQ504; and the potential benefits of EQ504. Because such statements are subject to risks and uncertainties, many of which are outside of Equillium’s control, actual results may differ materially from those expressed or implied by such forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking statements include: Equillium’s ability to execute its plans and strategies; Equillium’s ability to continue as a going concern; risks related to performing clinical and pre-clinical studies; whether the results from clinical and pre-clinical studies will validate and support the safety and efficacy of Equillium’s product candidates; changes in the competitive landscape; and Equillium’s ability to raise sufficient financing, which may not be available on acceptable terms or at all, to advance EQ504 and fund Equillium’s strategic plans. These and other risks and uncertainties are described more fully under the caption “Risk Factors” and elsewhere in Equillium’s filings and reports, which may be accessed for free by visiting the Securities and Exchange Commission’s website and on Equillium’s website under the heading “Investors.” Investors should take such risks into account and should not rely on forward-looking statements when making investment decisions. All forward-looking statements contained in this press release speak only as of the date on which they were made. Equillium undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

Investor Contact
PJ Kelleher
LifeSci Advisors, LLC
+1-617-430-7579
pkelleher@lifesciadvisors.com 

Former Particle CTO brings deep cellular and IoT leadership to drive Inseego’s global engineering operations and execution, including those from the acquisition of Nokia’s Fixed Wireless Access business

SAN DIEGO, Sept. 29, 2026 (GLOBE NEWSWIRE) — Inseego Corp. (Nasdaq: INSG), a global leader in wireless broadband connectivity, today announced that Nick Lambourne has joined the company as Chief Technology Officer. Lambourne will lead Inseego’s global engineering organization across hardware, embedded software, and cloud platforms as the company expands its scale and global footprint through its planned acquisition of Nokia’s Fixed Wireless Access business.

Lambourne has led the development of cellular and connected products across hardware, embedded software, cloud services, mobile applications, and manufacturing. That background is particularly relevant as Inseego brings its existing and incoming Nokia FWA engineering operations together into a single global engineering organization and aligns how it develops and delivers products for service provider and enterprise customers.

Most recently, Lambourne was CTO of Particle, where he helped build an enterprise IoT business that paired connected hardware with recurring software services and helped guide the company’s integration following its acquisition by Digi International. Prior to that, he held engineering and business leadership roles at Roku, Automatic, and SiriusXM, led Android platform development at Broadcom, and began his career developing cellular silicon for Nokia and Samsung phones.

“Nick joins Inseego at an important moment as we focus on operating on a global scale,” said Juho Sarvikas, CEO of Inseego. “His deep cellular expertise and experience across hardware, software, cloud, and international engineering operations will be critical as we strengthen our product delivery and enter our next chapter as a global wireless broadband company. Nick will also lead our efforts to accelerate AI across the entire software cycle.”

“Inseego has a rare depth of technology, spanning hardware, embedded software, cloud services, and customer experience,” said Nick Lambourne, Chief Technology Officer of Inseego. “Having recently led work on Qualcomm-based platforms, I’m excited to roll up my sleeves with the team, learn our customers’ goals, and build a strong engineering organization that delivers with consistency and discipline.”

Lambourne succeeds Vishal Donthireddy, who is leaving Inseego after more than two decades with the company. Inseego thanks Donthireddy for his leadership and significant contributions over that time.

About Inseego

Inseego is a global leader in wireless broadband, delivering fast, reliable connectivity to homes, businesses, and people on the move. With the acquisition of Nokia’s FastMile fixed wireless access product, Inseego offers one of the industry’s broadest cellular broadband portfolios, spanning fixed wireless gateways, mobile hotspots and routers, enterprise and industrial gateways, and cloud-based device, network, and subscriber management software. Backed by decades of wireless engineering expertise across 5G, Wi-Fi, antenna design, and cloud software, Inseego partners with mobile network operators worldwide to deliver connectivity at scale. Headquartered in San Diego, California, Inseego has offices in Amsterdam, Bangalore, and Athens. Learn more at www.inseego.com.  

Media Relations Contact: 
pr@inseego.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/7d673237-8cf4-4cf4-bda0-9e859782adeb